Purevax RCCh

RSS

vaccine against feline viral rhinotracheitis, feline calicivirosis and feline Chlamydophila infections

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Purevax RCCh has lapsed because it has not been marketed in the European Union in the three years following the granting of the authorisation.

This EPAR was last updated on 22/01/2015

Authorisation details

Product details
Name
Purevax RCCh
Agency product number
EMEA/V/C/000092
Active substance
Attenuated feline rhinotracheitis herpesvirus (FHV F2 strain), inactivated feline Calicivirosis antigens (FCV 431 and G1 strains), attenuated Chlamydophila felis (905 strain)
International non-proprietary name (INN) or common name
vaccine against feline viral rhinotracheitis, feline calicivirosis and feline Chlamydophila infections
Species
Cats
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI06AH
Publication details
Marketing-authorisation holder
Merial
Revision
8
Date of issue of marketing authorisation valid throughout the European Union
22/02/2005
Contact address

29 Avenue Tony Garnier
69007 Lyon
France

Product information

12/02/2014 Purevax RCCh - EMEA/V/C/000092 - R/0007

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Immunologicals for felidae

Therapeutic indication

Active immunisation of cats aged 8 weeks and older:

  • against feline viral rhinotracheitis to reduce clinical signs;
  • against calicivirus infection to reduce clinical signs and excretion;
  • against Chlamydophila felis infection to reduce clinical signs.

Onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis, calicivirus and Chlamydophila felis components.

The duration of immunity is 1 year after the last (re-)vaccination.

Assessment history

How useful was this page?

Add your rating